University Hospital Heidelberg

klinikum.uni-heidelberg.de

Total trials

175

Active

53

Phase 3

5

Total enrollment

117,300

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
CETEG1
PCV1
Sacituzumab Govitecan1
Physicians Choice (PhC).1
Atezolizumab 1200 mg abs day 1 q221
Nivolumab and Entinostat1
Chemotherapy1
CD19.CAR T Cells1
Fludarabine1
Cyclophosphamide1
Signifor1
Cyclosporine A1

Next readouts

  • 2024-11-30
  • 2026-06-30
  • 2026-12-31
  • 2027-02
  • 2027-10
  • 2028-01
  • 2028-08-01
  • 2033-03-31

Top conditions

  • Ischemic Stroke9
  • Coronary Artery Disease7
  • Cancer6
  • Atrial Fibrillation5
  • Prostate Cancer3
  • Acute Myeloid Leukemia3
  • Head and Neck Cancer3
  • Hemorrhagic Stroke3

Frequently asked questions about University Hospital Heidelberg

How many clinical trials does University Hospital Heidelberg have on ClinicalTrials.gov?
University Hospital Heidelberg is listed as the lead sponsor on 175 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
How many of University Hospital Heidelberg's trials are in Phase 3?
5 of University Hospital Heidelberg's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does University Hospital Heidelberg focus on?
University Hospital Heidelberg's most-studied conditions on ClinicalTrials.gov are Ischemic Stroke, Coronary Artery Disease, Cancer, Atrial Fibrillation, Prostate Cancer.
When are University Hospital Heidelberg's next clinical trial readouts?
University Hospital Heidelberg has 8 upcoming primary-completion readouts tracked here; the soonest is “Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC”, expected around 2024-11-30.